Company registration number: 14185668

Lina Medical Product Management Limited

Contents

Balance Sheet	1
Notes to the Financial Statements	2 to 6

Lina Medical Product Management Limited

(Registration number: 14185668)
Balance Sheet as at 30 June 2026

	Note	2026 £	2025 £
Fixed assets
Tangible assets	4	516,538	506,194
Current assets
Debtors	5	59,438	114,679
Cash at bank and in hand		17,280	43,664
		76,718	158,343
Creditors: Amounts falling due within one year	6	(501,017)	(612,417)
Net current liabilities		(424,299)	(454,074)
Total assets less current liabilities		92,239	52,120
Provisions for liabilities
Deferred tax liabilities		(12,232)	(12,232)
Net assets		80,007	39,888
Capital and reserves
Called up share capital		100	100
Profit and loss account		79,907	39,788
Total equity		80,007	39,888

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 29 October 2026 .
 

S D Kornerup Director

Lina Medical Product Management Limited

Notes to the Financial Statements
for the Year Ended 30 June 2026

1	General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Swaines Hill Manor
South Warnborough
Alton
Hampshire
GU34 4DP

2	Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

These financial statements are presented in Sterling (£).

Turnover recognition

Turnover represents amounts invoiced during the year net of VAT.

Turnover is in respect of inter-group recharges and is recognised in accordance with the accruals basis.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Lina Medical Product Management Limited

Notes to the Financial Statements
for the Year Ended 30 June 2026

Tax

Tax is recognised in the profit and loss account, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised on timing differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements and on unused tax losses or tax credits in the company. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

The carrying amount of deferred tax assets are reivewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

Deferred tax liabilities are presented within provisions for liabilities on the balance sheet.

Tangible assets

Tangible assets are stated at cost, less accumulated depreciation and accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation of tangible assets

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class	Depreciation method and rate
Motor vehicles	20% straight line
Short term leasehold property	Over the life of the lease
Properties under construction	Not depreciated until work complete

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Lina Medical Product Management Limited

Notes to the Financial Statements
for the Year Ended 30 June 2026

Creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade and other creditors, relating primarily to group balances, are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Intercompany Balances

The company has balances with other members of the wider group. These are initially measured at
transaction price and any debtor balances are subsequently reviewed for impairment.

Interest is charged on balances older than 60 days, this is recognised in the profit and loss account.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Defined contribution pension obligation

The company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the company pays fixed contributions into a separate entity. Once the contributions have been paid the company has no further payments obligations.

The contributions are recognised as an expense in the profit and loss account when they fall due. Amounts not paid are shown in accruals as a liability in the balance sheet. The assets of the plan are held separately from the company in independently administered funds.

3	Staff numbers

The average number of persons employed by the company (including the director) during the year was 9 (2025 - 9).

Lina Medical Product Management Limited

Notes to the Financial Statements
for the Year Ended 30 June 2026

4	Tangible assets

	Land and buildings £	Motor vehicles  £	Properties under construction  £	Total £
Cost or valuation
At 1 July 2025	439,871	61,159	29,628	530,658
Additions	5,476	64,226	41,117	110,819
Disposals	-	-	(23,628)	(23,628)
Transfers	(5,500)	-	5,500	-
At 30 June 2026	439,847	125,385	52,617	617,849
Depreciation
At 1 July 2025	-	24,464	-	24,464
Charge for the year	54,981	21,866	-	76,847
At 30 June 2026	54,981	46,330	-	101,311
Carrying amount
At 30 June 2026	384,866	79,055	52,617	516,538
At 30 June 2025	439,871	36,695	29,628	506,194

Included within the net book value of land and buildings above is £Nil (2025 - £Nil) in respect of freehold land and buildings and £384,866 (2025 - £439,871) in respect of short leasehold land and buildings.
 

5

Debtors

	2026 £	2025 £
Amounts owed by group undertakings and undertakings in which the company has a participating interest	113	109
Prepayments	14,716	13,588
Other debtors	44,609	100,982
	59,438	114,679

Lina Medical Product Management Limited

Notes to the Financial Statements
for the Year Ended 30 June 2026

6

Creditors

Creditors: amounts falling due within one year

	2026 £	2025 £
Trade creditors	217,756	345,730
Amounts owed to group undertakings and undertakings in which the company has a participating interest	152,441	122,271
Taxation and social security	30,345	27,438
Other creditors	100,475	116,978
	501,017	612,417

7	Financial commitments, guarantees and contingencies

Amounts not provided for in the balance sheet

The total amount of financial commitments not included in the balance sheet is £736,355 (2025 - £883,626) as a lessee. The company has a related commitment as a lessor of £810,450 (2025 - £552,240).

8	Related party transactions

Transactions with the director

2026	At 1 July 2025 £	Advances to director £	Repayments by director £	At 30 June 2026 £
S D Kornerup
Current account upon which interest is charged	37,370	60,700	(53,462)	44,608

2025	At 1 July 2024 £	Advances to director £	Repayments by director £	At 30 June 2025 £
S D Kornerup
Current account upon which interest is charged	27,095	46,397	(36,122)	37,370

9	Audit Report

The Independent Auditor's Report was unqualified. The name of the Senior Statutory Auditor who signed the audit report on 29 October 2026 was Robert Oram BFP FCA, who signed for and on behalf of Albert Goodman LLP.